Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

TransMedics (TMDX) Long-Term Debt Repayments (2018)

TransMedics has reported Long-Term Debt Repayments over the past 1 years, most recently at $6.7 million for Q2 2018.

For Q2 2018, Long-Term Debt Repayments changed N/A year-over-year to $6.7 million; the TTM value through Dec 2022 reached $6.7 million, changed N/A, while the annual FY2022 figure was $36.0 million, N/A changed from the prior year.
Long-Term Debt Repayments for Q2 2018 was $6.7 million at TransMedics, up from $892000.0 in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $6.7 million in Q2 2018 and troughed at $892000.0 in Q1 2018.